The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Abstract
BACKGROUND: Vancomycin treatment failure in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is not uncommon, even when MRSA is susceptible to vancomycin. The aim of our study was to evaluate whether vancomycin minimum inhibitory concentration has any influence on the mortality associated with MRSA bacteremia. METHODS: A total of 414 episodes of MRSA bacteremia were prospectively followed-up from 1991 through 2005. MIC of vancomycin for the first isolate was determined by E-test. Clinical variables recorded were age, comorbidity, prior administration of vancomycin, use of corticosteroids, prognosis of underlying disease, source of bacteremia, the need for mechanical ventilation, shock, and mortality. A "treatment group" variable was created and defined as follows: (1) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1 microg/mL (38 episodes), (2) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1.5 microg/mL (90 episodes), (3) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 microg/mL (40 episodes), and (4) receipt of inappropriate empirical therapy (246 episodes). Univariate and multivariate analyses were performed. RESULTS: Episodes caused by strains with a vancomycin MIC of 2 microg/mL were independently associated with a lower risk of shock (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.15-0.75). Multivariate analysis selected receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 microg/mL (OR, 6.39; 95% CI, 1.68-24.3), receipt of inappropriate empirical therapy (OR, 3.62; 95% CI, 1.20-10.9), increasing age (OR, 1.02; 95% CI, 1.00-1.04), use of corticosteroids (OR, 1.85; 95% CI, 1.04-3.29), an ultimately (OR, 10.2; 95% CI, 2.85-36.8) or rapidly (OR, 1.81; 95% CI, 1.06-3.10) fatal underlying disease, high-risk (OR, 3.60; 95% CI, 1.89-6.88) and intermediate-risk (OR, 2.18; 95% CI, 1.17-4.04) sources of bacteremia, and shock (OR, 7.38; 95% CI, 4.11-13.3) as the best predictors of mortality. CONCLUSIONS: Mortality associated with MRSA bacteremia was significantly higher when the empirical antibiotic was inappropriate and when vancomycin was empirically used for treatment of infection with strains with a high vancomycin MIC (>1 microg/mL).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Lodise, T. P., McKinnon, P. S., Swiderski, L., & Rybak, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375057 · Cited by 604
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Gram-Negative Bacteremia: II. Clinical, Laboratory, and Therapeutic Observations
McCABE, W. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620240038007 · Cited by 384
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332
Liu, C., & Chambers, H. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3040-3045.2003 · Cited by 321
Walsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., & Diekema, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2439-2444.2001 · Cited by 319
Mortality Associated with Nosocomial Bacteremia Due to Methicillin-Resistant Staphylococcus aureus
Romero-Vivas, J., Rubio, M., Fernandez, C., & Picazo, J. J. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.6.1417 · Cited by 318
Pathogenic Significance of Methicillin Resistance for Patients with Staphylococcus aureus Bacteremia
Soriano, A., Martinez, J. A., Mensa, J., Marco, F., Almela, M., Moreno-Martinez, A., Sanchez, F., Munoz, I., Jimenez de Anta, M. T., & Soriano, E. (2000) · Clinical Infectious Diseases · doi:10.1086/313650 · Cited by 256
Self-citationCui, L., Iwamoto, A., Lian, J.-Q., Neoh, H.-M., Maruyama, T., Horikawa, Y., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.428-438.2006 · Cited by 240
Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-06 · Cited by 225
Jeffres, M. N., Isakow, W., Doherty, J. A., McKinnon, P. S., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2006) · Chest · doi:10.1378/chest.130.4.947 · Cited by 219
The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus Aureus
Walsh, T. R., & Howe, R. A. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160806 · Cited by 215
Wyllie, D. H., Crook, D. W., & Peto, T. E. A. (2006) · BMJ · doi:10.1136/bmj.38834.421713.2f · Cited by 210
Mohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185
Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy
Sakoulas, G., Moellering, R. C., & Eliopoulos, G. M. (2006) · Clinical Infectious Diseases · doi:10.1086/491713 · Cited by 165
Sakoulas, G., Gold, H. S., Cohen, R. A., Venkataraman, L., Moellering, R. C., & Eliopoulos, G. M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl030 · Cited by 149
Pfeltz, R. F., Singh, V. K., Schmidt, J. L., Batten, M. A., Baranyk, C. S., Nadakavukaren, M. J., Jayaswal, R. K., & Wilkinson, B. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.294-303.2000 · Cited by 134
Roghmann, M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.1001 · Cited by 130
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections
Moise, P. A., & Schentag, J. J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00303-4 · Cited by 118
Cepeda, J. A., Whitehouse, T., Cooper, B., Hails, J., Jones, K., Kwaku, F., Taylor, L., Hayman, S., Shaw, S., Kibbler, C., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh048 · Cited by 114
Robert, J., Bismuth, R., & Jarlier, V. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki486 · Cited by 98
Kim, H. B., Park, W.-B., Lee, K.-D., Kang, C.-I., Bang, J.-W., Hong-Bin, K., Kim, E.-C., Oh, M.-D., & Kang-Won, C. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh366 · Cited by 82
Khosrovaneh, A., RIEDERER, K. M., Saeed, S., Tabriz, M. S., Shah, A. R., Hanna, M., Sharma, M., Johnson, L. B., Fakih, M. G., & Khatib, R. (2004) · Clinical Infectious Diseases · doi:10.1086/383036 · Cited by 66
A Mouse Peritonitis Model for the Study of Glycopeptide Efficacy in GISA Infections
Doménech, A., Ribes, S., Cabellos, C., Domínguez, M. Á., Montero, A., Liñares, J., Ariza, J., & Gudiol, F. (2004) · Microbial Drug Resistance · doi:10.1089/mdr.2004.10.346 · Cited by 23
Bujdáková, H., Klimáčková, J., Allerberger, F. J., Moravčı́ková, M., Bagová, M., Hanzen, J., Michalkova-Papajova, D., Dierich, M. P., & Kettner, M. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00195-3 · Cited by 18
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., & Leibovici, L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00627-10 · Cited by 724
Metadata
- Authors
- Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-15
- Volume
- 46
- Issue
- 2
- Pages
- 193-200
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2114585210
- Cited by
- 767
- References
- 36
- FWCI
- 42.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.